Contact: Jim Barlow
jebarlow@uoregon.edu
541-346-3481
University of Oregon

J. Andrew Berglund, University of Oregon

Caption: Andrew Berglund, a member of the University of Oregon's Institute of Molecular Biology, studies myotonic dystrophy. His team has found an existing FDA-approved compound for a variety of diseases might be modified to treat RNA slicing defects that lead to the disease.

Credit: Photo by Jim Barlow

Usage Restrictions: None

Related news release: Possible help in fight against muscle-wasting disease